| Literature DB >> 26481149 |
Paulus Kirchhof1, Günter Breithardt2, Jeroen Bax3, Gerlinde Benninger4, Carina Blomstrom-Lundqvist5, Giuseppe Boriani6, Axel Brandes7, Helen Brown8, Martina Brueckmann9, Hugh Calkins10, Melanie Calvert11, Vincent Christoffels12, Harry Crijns13, Dobromir Dobrev14, Patrick Ellinor15, Larissa Fabritz16, Thomas Fetsch17, S Ben Freedman18, Andrea Gerth19, Andreas Goette20, Eduard Guasch21, Guido Hack22, Laurent Haegeli23, Stephane Hatem24, Karl Georg Haeusler25, Hein Heidbüchel26, Jutta Heinrich-Nols27, Francoise Hidden-Lucet28, Gerd Hindricks29, Steen Juul-Möller30, Stefan Kääb31, Lukas Kappenberger32, Stefanie Kespohl33, Dipak Kotecha11, Deirdre A Lane11, Angelika Leute4, Thorsten Lewalter34, Ralf Meyer35, Lluis Mont21, Felix Münzel36, Michael Nabauer19, Jens C Nielsen37, Michael Oeff38, Jonas Oldgren39, Ali Oto40, Jonathan P Piccini41, Art Pilmeyer42, Tatjana Potpara43, Ursula Ravens44, Holger Reinecke45, Thomas Rostock46, Joerg Rustige30, Irene Savelieva47, Renate Schnabel48, Ulrich Schotten49, Lars Schwichtenberg33, Moritz F Sinner50, Gerhard Steinbeck51, Monika Stoll52, Luigi Tavazzi53, Sakis Themistoclakis54, Hung Fat Tse55, Isabelle C Van Gelder56, Panagiotis E Vardas57, Timo Varpula58, Alphons Vincent35, David Werring59, Stephan Willems48, André Ziegler60, Gregory Y H Lip11, A John Camm47.
Abstract
At least 30 million people worldwide carry a diagnosis of atrial fibrillation (AF), and many more suffer from undiagnosed, subclinical, or 'silent' AF. Atrial fibrillation-related cardiovascular mortality and morbidity, including cardiovascular deaths, heart failure, stroke, and hospitalizations, remain unacceptably high, even when evidence-based therapies such as anticoagulation and rate control are used. Furthermore, it is still necessary to define how best to prevent AF, largely due to a lack of clinical measures that would allow identification of treatable causes of AF in any given patient. Hence, there are important unmet clinical and research needs in the evaluation and management of AF patients. The ensuing needs and opportunities for improving the quality of AF care were discussed during the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference in Nice, France, on 22 and 23 January 2015. Here, we report the outcome of this conference, with a focus on (i) learning from our 'neighbours' to improve AF care, (ii) patient-centred approaches to AF management, (iii) structured care of AF patients, (iv) improving the quality of AF treatment, and (v) personalization of AF management. This report ends with a list of priorities for research in AF patients. Published on behalf of the European Society of Cardiology. All rights reserved.Entities:
Keywords: Antiarrhythmic drugs; Anticoagulation; Atrial fibrillation; Bleeding; Cardiovascular risk; Catheter ablation; Outcomes; Quality of care; Rate control; Research; Research priorities
Mesh:
Year: 2015 PMID: 26481149 DOI: 10.1093/europace/euv304
Source DB: PubMed Journal: Europace ISSN: 1099-5129 Impact factor: 5.214